Kuvan
About Kuvan
Kuvan is a Healthcare company, and was acquired by BioMarin Pharmaceutical in December 2007. Its focus areas include Traditional Pharmaceuticals.
Company details
Provider of prescription medication for phenylketonuria (PKU). This medication is used to lower blood Phe levels in adults and children over one month of age with a specific type of PKU, in conjunction with a Phe-restricted diet. The medication offers various dosage forms and is supported by resources including clinical coordinators and educational materials. It addresses the management of PKU through a combination of pharmaceutical intervention and dietary control. The company also provides a trial program for eligible patients. Important safety information and potential side effects are clearly communicated.
- Stage Acquired
- SectorsHealthcare
- Website category Health · Pharmacy
- Website kuvan.com
- Acquired by BioMarin Pharmaceutical (Dec 2007)
- Investors
- Acquired byBioMarin Pharmaceutical
(Dec 2007)
Investors in Kuvan
Kuvan has secured backing from 1 investor. Prominent investors backing the company include BioMarin Pharmaceutical.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Therapeutics for rare genetic diseases are developed by BioMarin Pharmaceutical. | 1997 | biomarin.com | San Rafael, United States |
Investor details for Kuvan
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Web traffic of Kuvan
The website of Kuvan (kuvan.com) receives about 5.6K visits a month and ranks #4,438,219 among all websites worldwide, #4,425 in Pharmacy.
- Monthly visits5.6K
▲ 37.5% vs previous month
- Unique visitors1.7K
per month
- Global rank#4,438,219
among all websites
- Category rank#4,425
Health · Pharmacy
- Bounce rate40%
- Pages per visit1.7
- Average visit24 sec
- DevicesDesktop 36% · Mobile 64%
Websites whose visitors overlap most with Kuvan. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
pku.com | pku.com | 100% | – | ||
| npkua.org | 72% | 5.9K | #3,572,514 | View details | |
pkunews.org | pkunews.org | 72% | #3,429,657 | – | |
bmrn.com | bmrn.com | 68% | #5,261,449 | – | |
 meupku.wordpress.com | meupku.wordpress.com | 66% | #5,627,848 | – | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 8 similar websites and full traffic analytics for Kuvan
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 8 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Kuvan
Provider of prescription medication for phenylketonuria (PKU). This medication is used to lower blood Phe levels in adults and children over one month of age with a specific type of PKU, in conjunction with a Phe-restricted diet. The medication offers various dosage forms and is supported by resources including clinical coordinators and educational materials. It addresses the management of PKU through a combination of pharmaceutical intervention and dietary control. The company also provides a trial program for eligible patients. Important safety information and potential side effects are clearly communicated.
Kuvan has 1 investor. Key investors include BioMarin Pharmaceutical.
Yes. Kuvan was acquired by BioMarin Pharmaceutical in December 2007.